Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Brentuximab Vedotin e Nivolumab con o senza Ipilimumab nel trattamento di pazienti con linfoma di Hodgkin recidivante o refrattario

11 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Uno studio di fase I con una coorte di espansione/studio di fase II randomizzato sulle combinazioni di ipilimumab, nivolumab e brentuximab vedotin in pazienti con linfoma di Hodgkin recidivante/refrattario

This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating patients with Hodgkin lymphoma that has returned after a period of improvement (recurrent) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. It is not known whether giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer cells.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the complete response (CR) rate for the regimens of brentuximab vedotin and nivolumab compared to brentuximab vedotin, ipilimumab, and nivolumab. (Phase II; adult cohort [aged >= 18 years]) III. To characterize the safety and toxicity of treatment combination in the pediatric population. (Phase II; pediatric cohort [aged 12-17 years])

SECONDARY OBJECTIVES:

I. To evaluate complete response (CR) rate, partial response (PR) rate and overall response rate (ORR), for the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the duration of remission (DOR) to these combinations and compare with the DOR achieved with the most recent prior systemic therapy. (Phase I) III. To evaluate the progression-free survival (PFS) and the overall survival (OS) in patients receiving the combination of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) IV. To evaluate the ORR, PR, and stable disease (SD) rate for the combinations of brentuximab vedotin and nivolumab and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II) V. To evaluate the DOR to these combinations and compare with the DOR achieved with the most recent prior systemic therapy. (Phase II) VI. To evaluate the 5 year PFS and OS in patients receiving the combinations of brentuximab vedotin and nivolumab and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II) VII. To further evaluate the safety and characterize the toxicity for the combinations of brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II)

CORRELATIVE STUDY OBJECTIVES:

I. To evaluate the ability of these combinations to alter tumor specific T cell immunity. (Phase I) II. To evaluate the effects of these combinations on systemic immunity. (Phase I) III. To evaluate a panel of cytokine and T cell specific biomarkers from the peripheral blood as a potential immune signature of treatment response to therapy with these combinations for patients with relapsed/refractory Hodgkin lymphoma (HL). (Phase I) IV. To evaluate using gene expression profiling (GEP) a signature of response to these novel combinations of an antibody drug conjugate with immunomodulatory therapy. (Phase I) V. To evaluate the ability of these combinations to alter tumor specific T cell immunity, and circulating T cell phenotypes, in patients as a function of treatment response at multiple timepoints during therapy. (Phase II) VI. To evaluate peripheral blood cytokine profiles in responding and resistant patients at multiple timepoints during therapy. (Phase II) VII. To evaluate using GEP a signature of response versus (vs.) resistance to these novel combinations of an antibody drug conjugate with immunomodulatory therapy. (Phase II) VIII. To evaluate the influence of human gut microbiome dysbiosis on HL lymphomagenesis and the systemic immune response. (Phase II)

IMAGING CORRELATIVE STUDY OBJECTIVES:

I. To evaluate atypical response patterns with currently available response evaluation criteria. (Phase II) II. To correlate response evaluated using currently available response evaluation criteria with duration of response (PFS, event free survival [EFS], failure free survival [FFS]). (Phase II) III. To evaluate response patterns in different immunotherapy treatment schemes and correlate with historical data using chemotherapy. (Phase II) IV. To correlate imaging changes in all treatment schemes quantitatively with PFS. (Phase II)

EXPLORATORY OBJECTIVES:

I. Evaluate outcomes (CR, PFS) between patients with/without prior transplants. (Phase II) II. Evaluate outcomes (PFS, OS) between the patients who stay on treatment and do not go to transplant in both arms (the post auto and the few others who don't want transplant) vs the patients who go off for transplant. (Phase II) III. Evaluate outcomes (CR, PFS) in pediatric population (age 12 to < 18 years of age) vs. adult population. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of brentuximab vedotin, ipilimumab, and nivolumab followed by a phase II study.

PHASE I: Patients are assigned into 1 of 3 arms.

ARM I: Patients receive brentuximab vedotin intravenously (IV) over 90 minutes on day 1 of cycles 1-16 and ipilimumab IV over 30 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity.

ARM III: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and nivolumab IV over 90 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity.

All patients also undergo computed tomography (CT) or positron emission tomography (PET) scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

After completion of phase I study treatment, patients are followed up every 3 months for 1 year, then every 6 months for 2 years. After completion of phase II study treatment, patients are followed up for 10 years.

Tipo di studio

Interventistico

Iscrizione (Stimato)

146

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233
        • University of Alabama at Birmingham Cancer Center
      • Birmingham, Alabama, Stati Uniti, 35233
        • Children's Hospital of Alabama
    • Alaska
      • Anchorage, Alaska, Stati Uniti, 98508
        • Anchorage Associates in Radiation Medicine
      • Anchorage, Alaska, Stati Uniti, 99508
        • Alaska Breast Care and Surgery LLC
      • Anchorage, Alaska, Stati Uniti, 99508
        • Alaska Oncology and Hematology LLC
      • Anchorage, Alaska, Stati Uniti, 99508
        • Alaska Women's Cancer Care
      • Anchorage, Alaska, Stati Uniti, 99508
        • Anchorage Oncology Centre
      • Anchorage, Alaska, Stati Uniti, 99508
        • Katmai Oncology Group
      • Anchorage, Alaska, Stati Uniti, 99508
        • Providence Alaska Medical Center
      • Anchorage, Alaska, Stati Uniti, 99504
        • Anchorage Radiation Therapy Center
      • Fairbanks, Alaska, Stati Uniti, 99701
        • Fairbanks Memorial Hospital
    • Arizona
      • Kingman, Arizona, Stati Uniti, 86401
        • Kingman Regional Medical Center
      • Phoenix, Arizona, Stati Uniti, 85004
        • Cancer Center at Saint Joseph's
    • Arkansas
      • Fort Smith, Arkansas, Stati Uniti, 72903
        • Mercy Hospital Fort Smith
      • Hot Springs, Arkansas, Stati Uniti, 71913
        • CHI Saint Vincent Cancer Center Hot Springs
    • California
      • Antioch, California, Stati Uniti, 94531
        • Kaiser Permanente-Deer Valley Medical Center
      • Arroyo Grande, California, Stati Uniti, 93420
        • PCR Oncology
      • Arroyo Grande, California, Stati Uniti, 93420
        • Mission Hope Medical Oncology - Arroyo Grande
      • Burbank, California, Stati Uniti, 91505
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • Dublin, California, Stati Uniti, 94568
        • Kaiser Permanente Dublin
      • Fremont, California, Stati Uniti, 94538
        • Kaiser Permanente-Fremont
      • Fresno, California, Stati Uniti, 93720
        • Kaiser Permanente-Fresno
      • Fresno, California, Stati Uniti, 93720
        • Fresno Cancer Center
      • Modesto, California, Stati Uniti, 95356
        • Kaiser Permanente-Modesto
      • Oakland, California, Stati Uniti, 94611
        • Kaiser Permanente-Oakland
      • Oakland, California, Stati Uniti, 94611
        • Kaiser Permanente Oakland-Broadway
      • Orange, California, Stati Uniti, 92868
        • Children's Hospital of Orange County
      • Palo Alto, California, Stati Uniti, 94304
        • Stanford Cancer Institute Palo Alto
      • Rancho Cordova, California, Stati Uniti, 95670
        • Kaiser Permanente-Rancho Cordova Cancer Center
      • Redwood City, California, Stati Uniti, 94063
        • Kaiser Permanente-Redwood City
      • Richmond, California, Stati Uniti, 94801
        • Kaiser Permanente-Richmond
      • Rohnert Park, California, Stati Uniti, 94928
        • Rohnert Park Cancer Center
      • Roseville, California, Stati Uniti, 95678
        • The Permanente Medical Group-Roseville Radiation Oncology
      • Roseville, California, Stati Uniti, 95661
        • Kaiser Permanente-Roseville
      • Sacramento, California, Stati Uniti, 95814
        • Kaiser Permanente Downtown Commons
      • Sacramento, California, Stati Uniti, 95823
        • Kaiser Permanente-South Sacramento
      • Sacramento, California, Stati Uniti, 95823
        • South Sacramento Cancer Center
      • Sacramento, California, Stati Uniti, 95825
        • Kaiser Permanente Sacramento Medical Center
      • San Francisco, California, Stati Uniti, 94115
        • Kaiser Permanente-San Francisco
      • San Francisco, California, Stati Uniti, 94158
        • UCSF Medical Center-Mission Bay
      • San Jose, California, Stati Uniti, 95119
        • Kaiser Permanente-Santa Teresa-San Jose
      • San Leandro, California, Stati Uniti, 94577
        • Kaiser Permanente San Leandro
      • San Luis Obispo, California, Stati Uniti, 93401
        • Pacific Central Coast Health Center-San Luis Obispo
      • San Rafael, California, Stati Uniti, 94903
        • Kaiser San Rafael-Gallinas
      • San Rafael, California, Stati Uniti, 94903
        • Kaiser Permanente-San Rafael
      • Santa Clara, California, Stati Uniti, 95051
        • Kaiser Permanente Medical Center - Santa Clara
      • Santa Maria, California, Stati Uniti, 93444
        • Mission Hope Medical Oncology - Santa Maria
      • Santa Rosa, California, Stati Uniti, 95403
        • Kaiser Permanente-Santa Rosa
      • South San Francisco, California, Stati Uniti, 94080
        • Kaiser Permanente Cancer Treatment Center
      • South San Francisco, California, Stati Uniti, 94080
        • Kaiser Permanente-South San Francisco
      • Stockton, California, Stati Uniti, 95210
        • Kaiser Permanente-Stockton
      • Vacaville, California, Stati Uniti, 95688
        • Kaiser Permanente Medical Center-Vacaville
      • Vallejo, California, Stati Uniti, 94589
        • Kaiser Permanente-Vallejo
      • Walnut Creek, California, Stati Uniti, 94596
        • Kaiser Permanente-Walnut Creek
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80012
        • Rocky Mountain Cancer Centers-Aurora
      • Aurora, Colorado, Stati Uniti, 80012
        • The Medical Center of Aurora
      • Boulder, Colorado, Stati Uniti, 80303
        • Boulder Community Foothills Hospital
      • Boulder, Colorado, Stati Uniti, 80304
        • Rocky Mountain Cancer Centers-Boulder
      • Centennial, Colorado, Stati Uniti, 80112
        • Rocky Mountain Cancer Centers - Centennial
      • Colorado Springs, Colorado, Stati Uniti, 80907
        • Penrose-Saint Francis Healthcare
      • Colorado Springs, Colorado, Stati Uniti, 80907
        • Rocky Mountain Cancer Centers-Penrose
      • Denver, Colorado, Stati Uniti, 80218
        • Presbyterian - Saint Lukes Medical Center - Health One
      • Denver, Colorado, Stati Uniti, 80218
        • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
      • Denver, Colorado, Stati Uniti, 80220
        • Rose Medical Center
      • Denver, Colorado, Stati Uniti, 80218
        • Rocky Mountain Cancer Centers-Midtown
      • Denver, Colorado, Stati Uniti, 80220
        • Rocky Mountain Cancer Centers-Rose
      • Denver, Colorado, Stati Uniti, 80204
        • Denver Health Medical Center
      • Denver, Colorado, Stati Uniti, 80218
        • Colorado Blood Cancer Institute
      • Denver, Colorado, Stati Uniti, 80204
        • Cancer Center of Colorado at Sloan's Lake
      • Denver, Colorado, Stati Uniti, 80209
        • The Women's Imaging Center
      • Denver, Colorado, Stati Uniti, 80206
        • National Jewish Health-Main Campus
      • Denver, Colorado, Stati Uniti, 80220
        • Western Surgical Care
      • Denver, Colorado, Stati Uniti, 80218
        • Saint Joseph Hospital - Cancer Centers of Colorado
      • Denver, Colorado, Stati Uniti, 80210
        • AdventHealth Porter
      • Durango, Colorado, Stati Uniti, 81301
        • Mercy Medical Center
      • Durango, Colorado, Stati Uniti, 81301
        • CommonSpirit Cancer Center Mercy
      • Englewood, Colorado, Stati Uniti, 80113
        • Mountain Blue Cancer Care Center - Swedish
      • Englewood, Colorado, Stati Uniti, 80113
        • Swedish Medical Center
      • Englewood, Colorado, Stati Uniti, 80113
        • Rocky Mountain Cancer Centers - Swedish
      • Golden, Colorado, Stati Uniti, 80401
        • Mountain Blue Cancer Care Center
      • Golden, Colorado, Stati Uniti, 80401
        • National Jewish Health-Western Hematology Oncology
      • Grand Junction, Colorado, Stati Uniti, 81501
        • Saint Mary's Hospital and Regional Medical Center
      • Greeley, Colorado, Stati Uniti, 80631
        • Banner North Colorado Medical Center
      • Lafayette, Colorado, Stati Uniti, 80026
        • Good Samaritan Hospital - Cancer Centers of Colorado
      • Lakewood, Colorado, Stati Uniti, 80228
        • Rocky Mountain Cancer Centers-Lakewood
      • Lakewood, Colorado, Stati Uniti, 80228
        • CommonSpirit Saint Anthony Hospital Cancer Center
      • Littleton, Colorado, Stati Uniti, 80120
        • Rocky Mountain Cancer Centers-Littleton
      • Littleton, Colorado, Stati Uniti, 80122
        • AdventHealth Littleton
      • Lone Tree, Colorado, Stati Uniti, 80124
        • Sky Ridge Medical Center
      • Lone Tree, Colorado, Stati Uniti, 80124
        • Rocky Mountain Cancer Centers-Sky Ridge
      • Longmont, Colorado, Stati Uniti, 80501
        • Longmont United Hospital
      • Longmont, Colorado, Stati Uniti, 80501
        • Rocky Mountain Cancer Centers-Longmont
      • Loveland, Colorado, Stati Uniti, 80539
        • Banner North Colorado Medical Center - Loveland Campus
      • Parker, Colorado, Stati Uniti, 80138
        • Rocky Mountain Cancer Centers-Parker
      • Parker, Colorado, Stati Uniti, 80138
        • AdventHealth Parker
      • Pueblo, Colorado, Stati Uniti, 81008
        • Rocky Mountain Cancer Centers - Pueblo
      • Thornton, Colorado, Stati Uniti, 80260
        • Rocky Mountain Cancer Centers-Thornton
      • Thornton, Colorado, Stati Uniti, 80260
        • National Jewish Health-Northern Hematology Oncology
      • Wheat Ridge, Colorado, Stati Uniti, 80401
        • Intermountain Health Lutheran Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • Children's National Medical Center
    • Florida
      • Fort Myers, Florida, Stati Uniti, 33905
        • Regional Cancer Center-Lee Memorial Health System
      • Fort Myers, Florida, Stati Uniti, 33908
        • Golisano Children's Hospital of Southwest Florida
      • St. Petersburg, Florida, Stati Uniti, 33701
        • Johns Hopkins All Children's Hospital
      • Tampa, Florida, Stati Uniti, 33606
        • Tampa General Hospital
      • Tampa, Florida, Stati Uniti, 33607
        • Saint Joseph's Hospital/Children's Hospital-Tampa
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, Stati Uniti, 30329
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
    • Hawaii
      • Honolulu, Hawaii, Stati Uniti, 96819
        • Kaiser Permanente Moanalua Medical Center
    • Idaho
      • Boise, Idaho, Stati Uniti, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Boise, Idaho, Stati Uniti, 83712
        • Saint Luke's Cancer Institute - Boise
      • Caldwell, Idaho, Stati Uniti, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Stati Uniti, 83814
        • Kootenai Health - Coeur d'Alene
      • Emmett, Idaho, Stati Uniti, 83617
        • Walter Knox Memorial Hospital
      • Fruitland, Idaho, Stati Uniti, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, Stati Uniti, 83642
        • Idaho Urologic Institute-Meridian
      • Meridian, Idaho, Stati Uniti, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, Stati Uniti, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa, Idaho, Stati Uniti, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, Stati Uniti, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Stati Uniti, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
      • Twin Falls, Idaho, Stati Uniti, 83301
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Alton, Illinois, Stati Uniti, 62002
        • OSF Saint Anthony's Health Center
      • Aurora, Illinois, Stati Uniti, 60504
        • Rush-Copley Medical Center
      • Bloomington, Illinois, Stati Uniti, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, Stati Uniti, 61520
        • Illinois CancerCare-Canton
      • Carbondale, Illinois, Stati Uniti, 62902
        • Memorial Hospital of Carbondale
      • Carterville, Illinois, Stati Uniti, 62918
        • SIH Cancer Institute
      • Carthage, Illinois, Stati Uniti, 62321
        • Illinois CancerCare-Carthage
      • Centralia, Illinois, Stati Uniti, 62801
        • Centralia Oncology Clinic
      • Chicago, Illinois, Stati Uniti, 60611
        • Northwestern University
      • Chicago, Illinois, Stati Uniti, 60612
        • University of Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • Rush MD Anderson Cancer Center
      • Danville, Illinois, Stati Uniti, 61832
        • Carle at The Riverfront
      • Decatur, Illinois, Stati Uniti, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, Stati Uniti, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Dixon, Illinois, Stati Uniti, 61021
        • Illinois CancerCare-Dixon
      • Effingham, Illinois, Stati Uniti, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, Stati Uniti, 62401
        • Carle Physician Group-Effingham
      • Eureka, Illinois, Stati Uniti, 61530
        • Illinois CancerCare-Eureka
      • Galesburg, Illinois, Stati Uniti, 61401
        • Western Illinois Cancer Treatment Center
      • Galesburg, Illinois, Stati Uniti, 61401
        • Illinois CancerCare-Galesburg
      • Joliet, Illinois, Stati Uniti, 60435
        • Duly Health and Care Joliet
      • Kewanee, Illinois, Stati Uniti, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb, Illinois, Stati Uniti, 61455
        • Illinois CancerCare-Macomb
      • Mattoon, Illinois, Stati Uniti, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Mount Vernon, Illinois, Stati Uniti, 62864
        • SSM Health Good Samaritan
      • O'Fallon, Illinois, Stati Uniti, 62269
        • Cancer Care Center of O'Fallon
      • Ottawa, Illinois, Stati Uniti, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin, Illinois, Stati Uniti, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Stati Uniti, 61636
        • Methodist Medical Center of Illinois
      • Peoria, Illinois, Stati Uniti, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, Stati Uniti, 61354
        • Illinois CancerCare-Peru
      • Peru, Illinois, Stati Uniti, 61354
        • Valley Radiation Oncology
      • Princeton, Illinois, Stati Uniti, 61356
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, Stati Uniti, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Stati Uniti, 62702
        • Springfield Clinic
      • Springfield, Illinois, Stati Uniti, 62781
        • Springfield Memorial Hospital
      • Swansea, Illinois, Stati Uniti, 62226
        • Southwest Illinois Health Services LLP
      • Urbana, Illinois, Stati Uniti, 61801
        • Carle Cancer Center
      • Urbana, Illinois, Stati Uniti, 61801
        • The Carle Foundation Hospital
      • Washington, Illinois, Stati Uniti, 61571
        • Illinois CancerCare - Washington
      • Yorkville, Illinois, Stati Uniti, 60560
        • Rush-Copley Healthcare Center
    • Indiana
      • Evansville, Indiana, Stati Uniti, 47713
        • Deaconess Clinic Downtown
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Indiana University/Melvin and Bren Simon Cancer Center
      • Newburgh, Indiana, Stati Uniti, 47630
        • Chancellor Center for Oncology
    • Iowa
      • Clive, Iowa, Stati Uniti, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, Stati Uniti, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Council Bluffs, Iowa, Stati Uniti, 51503
        • Alegent Health Mercy Hospital
      • Creston, Iowa, Stati Uniti, 50801
        • Greater Regional Medical Center
      • Des Moines, Iowa, Stati Uniti, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Stati Uniti, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • West Des Moines, Iowa, Stati Uniti, 50266
        • Mercy Medical Center-West Lakes
    • Kansas
      • Garden City, Kansas, Stati Uniti, 67846
        • Central Care Cancer Center - Garden City
      • Great Bend, Kansas, Stati Uniti, 67530
        • Central Care Cancer Center - Great Bend
    • Kentucky
      • Bardstown, Kentucky, Stati Uniti, 40004
        • CommonSpirit Saint Joseph Hospital - Bardstown
      • Corbin, Kentucky, Stati Uniti, 40701
        • Commonwealth Cancer Center-Corbin
      • Lexington, Kentucky, Stati Uniti, 40504
        • Saint Joseph Radiation Oncology Resource Center
      • Lexington, Kentucky, Stati Uniti, 40509
        • CommonSpirit Saint Joseph Medical Center - East Lexington
      • London, Kentucky, Stati Uniti, 40741
        • CommonSpirit Saint Joseph Hospital London
      • Louisville, Kentucky, Stati Uniti, 40202
        • Jewish Hospital
      • Louisville, Kentucky, Stati Uniti, 40245
        • UofL Health Medical Center Northeast
      • Louisville, Kentucky, Stati Uniti, 40215
        • Saints Mary and Elizabeth Hospital
      • Paducah, Kentucky, Stati Uniti, 42003
        • Mercy Health - Paducah Cancer Center
      • Shepherdsville, Kentucky, Stati Uniti, 40165
        • Jewish Hospital Medical Center South
    • Louisiana
      • Baton Rouge, Louisiana, Stati Uniti, 70805
        • LSU Health Baton Rouge-North Clinic
      • Baton Rouge, Louisiana, Stati Uniti, 70809
        • Louisiana Hematology Oncology Associates LLC
      • Baton Rouge, Louisiana, Stati Uniti, 70809
        • Mary Bird Perkins Cancer Center
      • Baton Rouge, Louisiana, Stati Uniti, 70808
        • Our Lady of The Lake
      • Baton Rouge, Louisiana, Stati Uniti, 70808
        • Our Lady of the Lake Physician Group
      • Covington, Louisiana, Stati Uniti, 70433
        • Northshore Oncology Associates-Covington
      • Houma, Louisiana, Stati Uniti, 70360
        • Terrebonne General Medical Center
      • Houma, Louisiana, Stati Uniti, 70360
        • Oncology Center of The South Incorporated
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
      • Baltimore, Maryland, Stati Uniti, 21229
        • Saint Agnes Hospital
      • Bethesda, Maryland, Stati Uniti, 20889-5600
        • Walter Reed National Military Medical Center
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02111
        • Tufts Medical Center
    • Michigan
      • Port Huron, Michigan, Stati Uniti, 48060
        • Lake Huron Medical Center
      • Port Huron, Michigan, Stati Uniti, 48060
        • Huron Medical Center PC
    • Minnesota
      • Aitkin, Minnesota, Stati Uniti, 56431
        • Riverwood Healthcare Center
      • Brainerd, Minnesota, Stati Uniti, 56401
        • Essentia Health Saint Joseph's Medical Center
      • Deer River, Minnesota, Stati Uniti, 56636
        • Essentia Health - Deer River Clinic
      • Detroit Lakes, Minnesota, Stati Uniti, 56501
        • Essentia Health Saint Mary's - Detroit Lakes Clinic
      • Duluth, Minnesota, Stati Uniti, 55805
        • Essentia Health Cancer Center
      • Duluth, Minnesota, Stati Uniti, 55805
        • Essentia Health Saint Mary's Medical Center
      • Duluth, Minnesota, Stati Uniti, 55805
        • Miller-Dwan Hospital
      • Fergus Falls, Minnesota, Stati Uniti, 56537
        • Lake Region Healthcare Corporation-Cancer Care
      • Fosston, Minnesota, Stati Uniti, 56542
        • Essentia Health - Fosston
      • Hibbing, Minnesota, Stati Uniti, 55746
        • Essentia Health Hibbing Clinic
      • Park Rapids, Minnesota, Stati Uniti, 56470
        • Essentia Health - Park Rapids
      • Rochester, Minnesota, Stati Uniti, 55905
        • Mayo Clinic in Rochester
      • Sandstone, Minnesota, Stati Uniti, 55072
        • Essentia Health Sandstone
      • Virginia, Minnesota, Stati Uniti, 55792
        • Essentia Health Virginia Clinic
    • Missouri
      • Ballwin, Missouri, Stati Uniti, 63011
        • Mercy Oncology and Hematology - Clayton-Clarkson
      • Bolivar, Missouri, Stati Uniti, 65613
        • Central Care Cancer Center - Bolivar
      • Bonne Terre, Missouri, Stati Uniti, 63628
        • Parkland Health Center-Bonne Terre
      • Branson, Missouri, Stati Uniti, 65616
        • Cox Cancer Center Branson
      • Cape Girardeau, Missouri, Stati Uniti, 63703
        • Saint Francis Medical Center
      • Cape Girardeau, Missouri, Stati Uniti, 63703
        • Mercy Cancer Center - Cape Girardeau
      • Chesterfield, Missouri, Stati Uniti, 63017
        • Saint Luke's Hospital
      • City of Saint Peters, Missouri, Stati Uniti, 63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, Stati Uniti, 63141
        • Siteman Cancer Center at West County Hospital
      • Farmington, Missouri, Stati Uniti, 63640
        • Parkland Health Center - Farmington
      • Jefferson City, Missouri, Stati Uniti, 65109
        • MU Health Care Goldschmidt Cancer Center
      • Joplin, Missouri, Stati Uniti, 64804
        • Freeman Health System
      • Joplin, Missouri, Stati Uniti, 64804
        • Mercy Hospital Joplin
      • Kansas City, Missouri, Stati Uniti, 64108
        • Children's Mercy Hospitals and Clinics
      • Rolla, Missouri, Stati Uniti, 65401
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Rolla, Missouri, Stati Uniti, 65401
        • Phelps Health Delbert Day Cancer Institute
      • Saint Joseph, Missouri, Stati Uniti, 64506
        • Heartland Regional Medical Center
      • Sainte Genevieve, Missouri, Stati Uniti, 63670
        • Sainte Genevieve County Memorial Hospital
      • Springfield, Missouri, Stati Uniti, 65807
        • CoxHealth South Hospital
      • Springfield, Missouri, Stati Uniti, 65804
        • Mercy Hospital Springfield
      • St Louis, Missouri, Stati Uniti, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Stati Uniti, 63129
        • Siteman Cancer Center-South County
      • St Louis, Missouri, Stati Uniti, 63136
        • Siteman Cancer Center at Christian Hospital
      • St Louis, Missouri, Stati Uniti, 63131
        • Missouri Baptist Medical Center
      • St Louis, Missouri, Stati Uniti, 63109
        • Mercy Infusion Center - Chippewa
      • St Louis, Missouri, Stati Uniti, 63141
        • Mercy Hospital Saint Louis
      • St Louis, Missouri, Stati Uniti, 63128
        • Mercy Hospital South
      • Sullivan, Missouri, Stati Uniti, 63080
        • Missouri Baptist Sullivan Hospital
      • Washington, Missouri, Stati Uniti, 63090
        • Mercy Hospital Washington
    • Montana
      • Anaconda, Montana, Stati Uniti, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Stati Uniti, 59101
        • Billings Clinic Cancer Center
      • Billings, Montana, Stati Uniti, 59101
        • Saint Vincent Healthcare
      • Billings, Montana, Stati Uniti, 59102
        • Saint Vincent Frontier Cancer Center
      • Bozeman, Montana, Stati Uniti, 59715
        • Bozeman Health Deaconess Hospital
      • Butte, Montana, Stati Uniti, 59701
        • Saint James Community Hospital and Cancer Treatment Center
      • Great Falls, Montana, Stati Uniti, 59405
        • Great Falls Clinic
      • Great Falls, Montana, Stati Uniti, 59405
        • Benefis Sletten Cancer Institute
      • Helena, Montana, Stati Uniti, 59601
        • Saint Peter's Community Hospital
      • Kalispell, Montana, Stati Uniti, 59901
        • Logan Health Medical Center
      • Missoula, Montana, Stati Uniti, 59802
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, Stati Uniti, 59804
        • Community Medical Center
    • Nebraska
      • Grand Island, Nebraska, Stati Uniti, 68803
        • Nebraska Cancer Specialists/Oncology Hematology West PC
      • Kearney, Nebraska, Stati Uniti, 68847
        • CHI Health Good Samaritan
      • Kearney, Nebraska, Stati Uniti, 68845
        • Fred and Pamela Buffett Cancer Center - Kearney
      • Lincoln, Nebraska, Stati Uniti, 68510
        • Saint Elizabeth Regional Medical Center
      • Omaha, Nebraska, Stati Uniti, 68124
        • Alegent Health Bergan Mercy Medical Center
      • Omaha, Nebraska, Stati Uniti, 68122
        • Alegent Health Immanuel Medical Center
      • Omaha, Nebraska, Stati Uniti, 68130
        • Alegent Health Lakeside Hospital
      • Omaha, Nebraska, Stati Uniti, 68122
        • Hematology and Oncology Consultants PC
      • Papillion, Nebraska, Stati Uniti, 68046
        • Midlands Community Hospital
    • Nevada
      • Carson City, Nevada, Stati Uniti, 89703
        • Carson Tahoe Regional Medical Center
      • Henderson, Nevada, Stati Uniti, 89052
        • Comprehensive Cancer Centers of Nevada - Henderson
      • Henderson, Nevada, Stati Uniti, 89052
        • Cancer and Blood Specialists-Henderson
      • Henderson, Nevada, Stati Uniti, 89052
        • Las Vegas Cancer Center-Henderson
      • Henderson, Nevada, Stati Uniti, 89074
        • Comprehensive Cancer Centers of Nevada-Southeast Henderson
      • Henderson, Nevada, Stati Uniti, 89052
        • Comprehensive Cancer Centers of Nevada-Horizon Ridge
      • Henderson, Nevada, Stati Uniti, 89074
        • Las Vegas Urology - Green Valley
      • Henderson, Nevada, Stati Uniti, 89074
        • Las Vegas Urology - Pebble
      • Henderson, Nevada, Stati Uniti, 89074
        • Urology Specialists of Nevada - Green Valley
      • Henderson, Nevada, Stati Uniti, 89074
        • Oncology Las Vegas - Henderson
      • Las Vegas, Nevada, Stati Uniti, 89144
        • Summerlin Hospital Medical Center
      • Las Vegas, Nevada, Stati Uniti, 89109
        • Sunrise Hospital and Medical Center
      • Las Vegas, Nevada, Stati Uniti, 89102
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, Stati Uniti, 89106
        • Radiation Oncology Centers of Nevada Central
      • Las Vegas, Nevada, Stati Uniti, 89119
        • Radiation Oncology Centers of Nevada Southeast
      • Las Vegas, Nevada, Stati Uniti, 89128
        • Comprehensive Cancer Centers of Nevada - Northwest
      • Las Vegas, Nevada, Stati Uniti, 89128
        • OptumCare Cancer Care at MountainView
      • Las Vegas, Nevada, Stati Uniti, 89135
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
      • Las Vegas, Nevada, Stati Uniti, 89144
        • Comprehensive Cancer Centers of Nevada - Town Center
      • Las Vegas, Nevada, Stati Uniti, 89144
        • Comprehensive Cancer Centers of Nevada-Summerlin
      • Las Vegas, Nevada, Stati Uniti, 89148
        • Comprehensive Cancer Centers of Nevada
      • Las Vegas, Nevada, Stati Uniti, 89169
        • Comprehensive Cancer Centers of Nevada - Central Valley
      • Las Vegas, Nevada, Stati Uniti, 89102
        • University Medical Center of Southern Nevada
      • Las Vegas, Nevada, Stati Uniti, 89106
        • Cancer and Blood Specialists-Shadow
      • Las Vegas, Nevada, Stati Uniti, 89109
        • HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
      • Las Vegas, Nevada, Stati Uniti, 89113
        • HealthCare Partners Medical Group Oncology/Hematology-San Martin
      • Las Vegas, Nevada, Stati Uniti, 89128
        • Cancer and Blood Specialists-Tenaya
      • Las Vegas, Nevada, Stati Uniti, 89128
        • HealthCare Partners Medical Group Oncology/Hematology-Tenaya
      • Las Vegas, Nevada, Stati Uniti, 89148-2405
        • Las Vegas Cancer Center-Medical Center
      • Las Vegas, Nevada, Stati Uniti, 89149
        • HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
      • Las Vegas, Nevada, Stati Uniti, 89128
        • Ann M Wierman MD LTD
      • Las Vegas, Nevada, Stati Uniti, 89074
        • Las Vegas Urology - Pecos
      • Las Vegas, Nevada, Stati Uniti, 89102
        • Desert West Surgery
      • Las Vegas, Nevada, Stati Uniti, 89103
        • Hope Cancer Care of Nevada
      • Las Vegas, Nevada, Stati Uniti, 89106
        • Urology Specialists of Nevada - Central
      • Las Vegas, Nevada, Stati Uniti, 89113
        • Las Vegas Prostate Cancer Center
      • Las Vegas, Nevada, Stati Uniti, 89113
        • Las Vegas Urology - Sunset
      • Las Vegas, Nevada, Stati Uniti, 89128
        • Las Vegas Urology - Cathedral Rock
      • Las Vegas, Nevada, Stati Uniti, 89128
        • Las Vegas Urology - Smoke Ranch
      • Las Vegas, Nevada, Stati Uniti, 89128
        • Urology Specialists of Nevada - Northwest
      • Las Vegas, Nevada, Stati Uniti, 89169
        • University Cancer Center
      • Las Vegas, Nevada, Stati Uniti, 89113
        • Urology Specialists of Nevada - Southwest
      • Las Vegas, Nevada, Stati Uniti, 89128
        • Oncology Las Vegas - Tenaya
      • Las Vegas, Nevada, Stati Uniti, 89183
        • OptumCare Cancer Care at Fort Apache
      • Pahrump, Nevada, Stati Uniti, 89048
        • Hope Cancer Care of Nevada-Pahrump
      • Reno, Nevada, Stati Uniti, 89502
        • Renown Regional Medical Center
      • Reno, Nevada, Stati Uniti, 89503
        • Saint Mary's Regional Medical Center
      • Reno, Nevada, Stati Uniti, 89509
        • Radiation Oncology Associates
    • New Jersey
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Hackensack University Medical Center
      • Lakewood, New Jersey, Stati Uniti, 08701
        • Monmouth Medical Center Southern Campus
      • Long Branch, New Jersey, Stati Uniti, 07740
        • Monmouth Medical Center
      • Morristown, New Jersey, Stati Uniti, 07960
        • Morristown Medical Center
      • New Brunswick, New Jersey, Stati Uniti, 08903
        • Rutgers Cancer Institute of New Jersey
      • New Brunswick, New Jersey, Stati Uniti, 08903
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87106
        • University of New Mexico Cancer Center
    • New York
      • Albany, New York, Stati Uniti, 12208
        • Albany Medical Center
      • Buffalo, New York, Stati Uniti, 14263
        • Roswell Park Cancer Institute
      • New York, New York, Stati Uniti, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Stati Uniti, 10029
        • Mount Sinai Hospital
      • New York, New York, Stati Uniti, 10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • New York, New York, Stati Uniti, 10065
        • NYP/Weill Cornell Medical Center
      • New York, New York, Stati Uniti, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Stony Brook, New York, Stati Uniti, 11794
        • Stony Brook University Medical Center
      • Syracuse, New York, Stati Uniti, 13210
        • State University of New York Upstate Medical University
      • The Bronx, New York, Stati Uniti, 10467
        • Montefiore Medical Center - Moses Campus
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Charlotte, North Carolina, Stati Uniti, 28203
        • Carolinas Medical Center/Levine Cancer Institute
      • Clinton, North Carolina, Stati Uniti, 28328
        • Southeastern Medical Oncology Center-Clinton
      • Goldsboro, North Carolina, Stati Uniti, 27534
        • Southeastern Medical Oncology Center-Goldsboro
      • Goldsboro, North Carolina, Stati Uniti, 27534
        • Wayne Memorial Hospital
      • Jacksonville, North Carolina, Stati Uniti, 28546
        • Southeastern Medical Oncology Center-Jacksonville
      • Jacksonville, North Carolina, Stati Uniti, 28546
        • Onslow Memorial Hospital
    • North Dakota
      • Fargo, North Dakota, Stati Uniti, 58103
        • Essentia Health Cancer Center-South University Clinic
      • Jamestown, North Dakota, Stati Uniti, 58401
        • Essentia Health - Jamestown Clinic
    • Ohio
      • Akron, Ohio, Stati Uniti, 44308
        • Children's Hospital Medical Center of Akron
      • Cincinnati, Ohio, Stati Uniti, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cincinnati, Ohio, Stati Uniti, 45220
        • Good Samaritan Hospital - Cincinnati
      • Cincinnati, Ohio, Stati Uniti, 45242
        • Bethesda North Hospital
      • Cincinnati, Ohio, Stati Uniti, 45247
        • TriHealth Cancer Institute-Westside
      • Cincinnati, Ohio, Stati Uniti, 45255
        • TriHealth Cancer Institute-Anderson
      • Cleveland, Ohio, Stati Uniti, 44109
        • MetroHealth Medical Center
      • Columbus, Ohio, Stati Uniti, 43205
        • Nationwide Children's Hospital
    • Oklahoma
      • Lawton, Oklahoma, Stati Uniti, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • University of Oklahoma Health Sciences Center
      • Oklahoma City, Oklahoma, Stati Uniti, 73120
        • Mercy Hospital Oklahoma City
      • Tulsa, Oklahoma, Stati Uniti, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Oregon
      • Baker City, Oregon, Stati Uniti, 97814
        • Saint Alphonsus Cancer Care Center-Baker City
      • Bend, Oregon, Stati Uniti, 97701
        • Saint Charles Health System
      • Clackamas, Oregon, Stati Uniti, 97015
        • Clackamas Radiation Oncology Center
      • Clackamas, Oregon, Stati Uniti, 97015
        • Providence Cancer Institute Clackamas Clinic
      • Coos Bay, Oregon, Stati Uniti, 97420
        • Bay Area Hospital
      • Newberg, Oregon, Stati Uniti, 97132
        • Providence Newberg Medical Center
      • Ontario, Oregon, Stati Uniti, 97914
        • Saint Alphonsus Cancer Care Center-Ontario
      • Oregon City, Oregon, Stati Uniti, 97045
        • Providence Willamette Falls Medical Center
      • Portland, Oregon, Stati Uniti, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Stati Uniti, 97225
        • Providence Saint Vincent Medical Center
      • Redmond, Oregon, Stati Uniti, 97756
        • Saint Charles Health System-Redmond
    • Pennsylvania
      • Hershey, Pennsylvania, Stati Uniti, 17033-0850
        • Penn State Milton S Hershey Medical Center
      • Philadelphia, Pennsylvania, Stati Uniti, 19111
        • Fox Chase Cancer Center
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Children's Hospital of Philadelphia
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • University of Pennsylvania/Abramson Cancer Center
    • South Carolina
      • Boiling Springs, South Carolina, Stati Uniti, 29316
        • Prisma Health Cancer Institute - Spartanburg
      • Columbia, South Carolina, Stati Uniti, 29203
        • Prisma Health Richland Hospital
      • Easley, South Carolina, Stati Uniti, 29640
        • Prisma Health Cancer Institute - Easley
      • Greenville, South Carolina, Stati Uniti, 29605
        • Prisma Health Cancer Institute - Faris
      • Greenville, South Carolina, Stati Uniti, 29607
        • Saint Francis Cancer Center
      • Greenville, South Carolina, Stati Uniti, 29615
        • Prisma Health Cancer Institute - Eastside
      • Greenville, South Carolina, Stati Uniti, 29605
        • Prisma Health Cancer Institute - Butternut
      • Greenville, South Carolina, Stati Uniti, 29601
        • Saint Francis Hospital
      • Greenville, South Carolina, Stati Uniti, 29605
        • BI-LO Charities Children's Cancer Center
      • Greenville, South Carolina, Stati Uniti, 29605
        • Prisma Health Greenville Memorial Hospital
      • Greer, South Carolina, Stati Uniti, 29650
        • Prisma Health Cancer Institute - Greer
      • Seneca, South Carolina, Stati Uniti, 29672
        • Prisma Health Cancer Institute - Seneca
    • Tennessee
      • Chattanooga, Tennessee, Stati Uniti, 37404
        • Memorial Hospital
      • Hixson, Tennessee, Stati Uniti, 37343
        • Pulmonary Medicine Center of Chattanooga-Hixson
      • Knoxville, Tennessee, Stati Uniti, 37916
        • East Tennessee Childrens Hospital
      • Memphis, Tennessee, Stati Uniti, 38105
        • Saint Jude Children's Research Hospital
      • Nashville, Tennessee, Stati Uniti, 37232
        • Vanderbilt University/Ingram Cancer Center
      • Nashville, Tennessee, Stati Uniti, 37203
        • The Children's Hospital at TriStar Centennial
      • Ooltewah, Tennessee, Stati Uniti, 37363
        • Memorial GYN Plus
    • Texas
      • Austin, Texas, Stati Uniti, 78723
        • Dell Children's Medical Center of Central Texas
      • Bryan, Texas, Stati Uniti, 77802
        • Saint Joseph Regional Cancer Center
      • Corpus Christi, Texas, Stati Uniti, 78411
        • Driscoll Children's Hospital
      • El Paso, Texas, Stati Uniti, 79905
        • El Paso Children's Hospital
      • Fort Worth, Texas, Stati Uniti, 76104
        • Cook Children's Medical Center
      • San Antonio, Texas, Stati Uniti, 78207
        • Children's Hospital of San Antonio
    • Utah
      • American Fork, Utah, Stati Uniti, 84003
        • American Fork Hospital / Huntsman Intermountain Cancer Center
      • Cedar City, Utah, Stati Uniti, 84720
        • Sandra L Maxwell Cancer Center
      • Logan, Utah, Stati Uniti, 84321
        • Logan Regional Hospital
      • Murray, Utah, Stati Uniti, 84107
        • Intermountain Medical Center
      • Ogden, Utah, Stati Uniti, 84403
        • McKay-Dee Hospital Center
      • Riverton, Utah, Stati Uniti, 84065
        • Riverton Hospital
      • Salt Lake City, Utah, Stati Uniti, 84106
        • Utah Cancer Specialists-Salt Lake City
      • Salt Lake City, Utah, Stati Uniti, 84143
        • LDS Hospital
      • St. George, Utah, Stati Uniti, 84770
        • Saint George Regional Medical Center
    • Virginia
      • Norfolk, Virginia, Stati Uniti, 23507
        • Children's Hospital of The King's Daughters
    • Washington
      • Aberdeen, Washington, Stati Uniti, 98520
        • Providence Regional Cancer System-Aberdeen
      • Auburn, Washington, Stati Uniti, 98001
        • MultiCare Auburn Medical Center
      • Bellevue, Washington, Stati Uniti, 98004
        • Overlake Medical Center
      • Bellingham, Washington, Stati Uniti, 98225
        • PeaceHealth Saint Joseph Medical Center
      • Burien, Washington, Stati Uniti, 98166
        • Saint Anne Hospital
      • Centralia, Washington, Stati Uniti, 98531
        • Providence Regional Cancer System-Centralia
      • Edmonds, Washington, Stati Uniti, 98026
        • Swedish Cancer Institute-Edmonds
      • Enumclaw, Washington, Stati Uniti, 98022
        • Saint Elizabeth Hospital
      • Everett, Washington, Stati Uniti, 98201
        • Providence Regional Cancer Partnership
      • Federal Way, Washington, Stati Uniti, 98003
        • Saint Francis Hospital
      • Gig Harbor, Washington, Stati Uniti, 98335
        • MultiCare Gig Harbor Medical Park
      • Issaquah, Washington, Stati Uniti, 98029
        • Swedish Cancer Institute-Issaquah
      • Kennewick, Washington, Stati Uniti, 99336
        • Kadlec Clinic Hematology and Oncology
      • Lacey, Washington, Stati Uniti, 98503
        • Providence Regional Cancer System-Lacey
      • Lakewood, Washington, Stati Uniti, 98499
        • Saint Clare Hospital
      • Longview, Washington, Stati Uniti, 98632
        • PeaceHealth Saint John Medical Center
      • Port Townsend, Washington, Stati Uniti, 98368
        • Jefferson Healthcare
      • Poulsbo, Washington, Stati Uniti, 98370
        • Harrison HealthPartners Hematology and Oncology-Poulsbo
      • Puyallup, Washington, Stati Uniti, 98372
        • MultiCare Good Samaritan Hospital
      • Renton, Washington, Stati Uniti, 98055
        • Valley Medical Center
      • Seattle, Washington, Stati Uniti, 98105
        • Seattle Children's Hospital
      • Seattle, Washington, Stati Uniti, 98107
        • Swedish Medical Center-Ballard Campus
      • Seattle, Washington, Stati Uniti, 98122
        • Swedish Medical Center-First Hill
      • Seattle, Washington, Stati Uniti, 98112
        • Kaiser Permanente Washington
      • Seattle, Washington, Stati Uniti, 98104
        • Pacific Gynecology Specialists
      • Seattle, Washington, Stati Uniti, 98122-5711
        • Swedish Medical Center-Cherry Hill
      • Sedro-Woolley, Washington, Stati Uniti, 98284
        • PeaceHealth United General Medical Center
      • Shelton, Washington, Stati Uniti, 98584
        • Providence Regional Cancer System-Shelton
      • Silverdale, Washington, Stati Uniti, 98383
        • Saint Joseph Medical Center Hematology and Oncology - Silverdale
      • Spokane, Washington, Stati Uniti, 99204
        • Providence Sacred Heart Medical Center and Children's Hospital
      • Spokane, Washington, Stati Uniti, 99204
        • MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
      • Spokane, Washington, Stati Uniti, 99218
        • MultiCare Deaconess Cancer and Blood Specialty Center - North
      • Spokane Valley, Washington, Stati Uniti, 99216
        • MultiCare Deaconess Cancer and Blood Specialty Center - Valley
      • Tacoma, Washington, Stati Uniti, 98405
        • Mary Bridge Children's Hospital and Health Center
      • Tacoma, Washington, Stati Uniti, 98405
        • Northwest Medical Specialties PLLC
      • Tacoma, Washington, Stati Uniti, 98431
        • Madigan Army Medical Center
      • Tacoma, Washington, Stati Uniti, 98405
        • MultiCare Tacoma General Hospital
      • Tacoma, Washington, Stati Uniti, 98405
        • Franciscan Research Center-Northwest Medical Plaza
      • Vancouver, Washington, Stati Uniti, 98664
        • PeaceHealth Southwest Medical Center
      • Walla Walla, Washington, Stati Uniti, 99362
        • Providence Saint Mary Regional Cancer Center
      • Yakima, Washington, Stati Uniti, 98902
        • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
      • Yelm, Washington, Stati Uniti, 98597
        • Providence Regional Cancer System-Yelm
    • West Virginia
      • Bridgeport, West Virginia, Stati Uniti, 26330
        • United Hospital Center
      • Martinsburg, West Virginia, Stati Uniti, 25401
        • WVUH-Berkely Medical Center
      • Morgantown, West Virginia, Stati Uniti, 26506
        • West Virginia University Healthcare
      • Parkersburg, West Virginia, Stati Uniti, 26101
        • Camden Clark Medical Center
    • Wisconsin
      • Ashland, Wisconsin, Stati Uniti, 54806
        • Duluth Clinic Ashland
      • Ashland, Wisconsin, Stati Uniti, 54806
        • Northwest Wisconsin Cancer Center
      • Burlington, Wisconsin, Stati Uniti, 53105
        • Aurora Cancer Care-Southern Lakes VLCC
      • Chippewa Falls, Wisconsin, Stati Uniti, 54729
        • Marshfield Clinic-Chippewa Center
      • Eau Claire, Wisconsin, Stati Uniti, 54701
        • Marshfield Medical Center-EC Cancer Center
      • Fond du Lac, Wisconsin, Stati Uniti, 54937
        • Aurora Health Center-Fond du Lac
      • Germantown, Wisconsin, Stati Uniti, 53022
        • Aurora Health Care Germantown Health Center
      • Grafton, Wisconsin, Stati Uniti, 53024
        • Aurora Cancer Care-Grafton
      • Green Bay, Wisconsin, Stati Uniti, 54311
        • Aurora BayCare Medical Center
      • Kenosha, Wisconsin, Stati Uniti, 53142
        • Aurora Cancer Care-Kenosha South
      • La Crosse, Wisconsin, Stati Uniti, 54601
        • Gundersen Lutheran Medical Center
      • Ladysmith, Wisconsin, Stati Uniti, 54848
        • Marshfield Medical Center - Ladysmith
      • Madison, Wisconsin, Stati Uniti, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Marinette, Wisconsin, Stati Uniti, 54143
        • Aurora Bay Area Medical Group-Marinette
      • Marshfield, Wisconsin, Stati Uniti, 54449
        • Marshfield Medical Center-Marshfield
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Medical College of Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53209
        • Aurora Cancer Care-Milwaukee
      • Milwaukee, Wisconsin, Stati Uniti, 53215
        • Aurora Saint Luke's Medical Center
      • Milwaukee, Wisconsin, Stati Uniti, 53233
        • Aurora Sinai Medical Center
      • Minocqua, Wisconsin, Stati Uniti, 54548
        • Marshfield Medical Center - Minocqua
      • Oshkosh, Wisconsin, Stati Uniti, 54904
        • Vince Lombardi Cancer Clinic - Oshkosh
      • Racine, Wisconsin, Stati Uniti, 53406
        • Aurora Cancer Care-Racine
      • Rice Lake, Wisconsin, Stati Uniti, 54868
        • Marshfield Medical Center-Rice Lake
      • Sheboygan, Wisconsin, Stati Uniti, 53081
        • Vince Lombardi Cancer Clinic-Sheboygan
      • Stevens Point, Wisconsin, Stati Uniti, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Summit, Wisconsin, Stati Uniti, 53066
        • Aurora Medical Center in Summit
      • Two Rivers, Wisconsin, Stati Uniti, 54241
        • Vince Lombardi Cancer Clinic-Two Rivers
      • Wausau, Wisconsin, Stati Uniti, 54401
        • Marshfield Clinic-Wausau Center
      • Wauwatosa, Wisconsin, Stati Uniti, 53226
        • Aurora Cancer Care-Milwaukee West
      • West Allis, Wisconsin, Stati Uniti, 53227
        • Aurora West Allis Medical Center
      • Weston, Wisconsin, Stati Uniti, 54476
        • Marshfield Medical Center - Weston
      • Wisconsin Rapids, Wisconsin, Stati Uniti, 54494
        • Marshfield Clinic - Wisconsin Rapids Center
    • Wyoming
      • Cheyenne, Wyoming, Stati Uniti, 82001
        • Cheyenne Regional Medical Center-West
      • Cody, Wyoming, Stati Uniti, 82414
        • Billings Clinic-Cody
      • Sheridan, Wyoming, Stati Uniti, 82801
        • Welch Cancer Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

12 anni e precedenti (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • PHASE I (ARMS A, B, C, D, E, F, G, H, I, X, Y, Z)

  • Age >= 18 years

  • Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including lymphocyte predominant (LP) HL are not permitted

  • Patients must have relapsed after first line chemotherapy; may have relapsed after autologous or allogeneic stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; if status post allogeneic stem cell transplant, no active graft versus host disease

  • Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis agents; patients in the nivolumab/brentuximab cohorts ONLY (D, E, F, Y) may have received prior ipilimumab

  • Patients may have received other prior activating immunotherapies (i.e. checkpoint inhibitors), but must not have received them within 6 months prior to registration, and there must be no serious unresolved complication of therapy at the time of registration; for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)

  • Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) performance status between 0-2

  • Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT) throughout the study

  • Patient must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all patients of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a patient of childbearing potential is anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

  • Patient of childbearing potential and/or sexually active patients must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both single barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for patients of childbearing potential) and for 7 months after the last dose of study drug (for patients who are sexually active with anyone of childbearing potential); should a patient become pregnant or suspect pregnancy while the patient or their partner is participating in this study, the patient (or the participating partner) should inform the treating physician immediately

  • Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air

  • Patients must have forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registration

  • Absolute neutrophil count (ANC) >= 1500/mcL (1.5 x 10^9/L) (obtained within 2 weeks prior to registration)

  • Platelets >= 75,000/mcL (75 x 10^9/L) (obtained within 2 weeks prior to registration)

  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) (obtained within 2 weeks prior to registration)

  • Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert's syndrome, for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within 2 weeks prior to registration)

  • Calculated creatinine clearance by Cockcroft-Gault formula >= 30 ml/min (obtained within 2 weeks prior to registration)

  • No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response

  • Patient must have no current or prior history of central nervous system (CNS) involvement

  • All prior therapy must have been completed at least 21 days prior to enrollment; no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed

  • No history of Steven's Johnson's syndrome, toxic epidermal necrolysis (TEN)s syndrome, or motor neuropathy

  • Human immunodeficiency virus (HIV) positive patients are allowed on this study if they have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded

  • Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed

    • Replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to initiation of study treatment are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study
    • Exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other CNS autoimmune disease (e.g., Multiple sclerosis); patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible
  • Patients must not have grade 2 or greater peripheral sensory neuropathy

  • Patients must not have New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia

  • Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab

  • Patients must not have a serious medical or psychiatric illness likely to interfere with study participation

  • Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration

  • Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment

  • Patients registering to Arms D, E, F, G, H, I, X, Y must not currently be smoking tobacco or other substances and must not have smoked within the past 6 months

  • RANDOMIZED PHASE II (ARMS K AND L): Age >= 12 years

    • Pediatric patients will include any patients < 18 years of age
  • RANDOMIZED PHASE II (ARMS K AND L): Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including lymphocyte predominant (LP) HL are not permitted

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must have relapsed after first line chemotherapy; may have relapsed after autologous stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; patient must not have received a prior allogeneic stem cell transplant (out of risk of reactivation of pulmonary graft versus host disease [GVHD])

  • RANDOMIZED PHASE II (ARMS K AND L): Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis agents; patients may not have received prior ipilimumab

  • RANDOMIZED PHASE II (ARMS K AND L): Patients may not have received other prior activating immunotherapies (i.e. checkpoint inhibitor therapies); for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)

  • RANDOMIZED PHASE II (ARMS K AND L): Adult patient (>= 18 years of age) ECOG-ACRIN performance status between 0-2

    • Pediatric patients (16-17 years of age) must have a Karnofsky performance level >= 50%
    • Pediatric patients (12-15 years of age) must have a Lansky performance level >= 50
  • RANDOMIZED PHASE II (ARMS K AND L): Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT) throughout the study

  • RANDOMIZED PHASE II (ARMS K AND L): Patient must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all patients of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

  • RANDOMIZED PHASE II (ARMS K AND L): Patient of childbearing potential and/or sexually active patient must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both double barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for patients of childbearing potential) and for 7 months after the last dose of study drug (for patients who are sexually active with anyone of childbearing potential); should a patient become pregnant or suspect pregnancy while the patient or their partner is participating in this study, the patient (or the participating partner) should inform the treating physician immediately

  • RANDOMIZED PHASE II (ARMS K AND L): Patients with impaired decision-making capacity are eligible with legally authorized representative

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must have FEV1/FVC > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registration

  • RANDOMIZED PHASE II (ARMS K AND L): ANC >= 1500/mcL (1.5 x 0^9/L) (obtained within 2 weeks prior to registration)

  • RANDOMIZED PHASE II (ARMS K AND L): Platelets >= 75,000/mcL (75 x 10^9/L) (obtained within 2 weeks prior to registration)

  • RANDOMIZED PHASE II (ARMS K AND L): AST/ALT =< 2.5 x upper limit of normal (ULN) for age (obtained within 2 weeks prior to registration)

  • RANDOMIZED PHASE II (ARMS K AND L): Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert's syndrome, for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within 2 weeks prior to registration)

  • RANDOMIZED PHASE II (ARMS K AND L): Adult patients (>= 18 years old) must have a calculated creatinine clearance by Cockcroft-Gault formula >= 30 ml/min (obtained within 2 weeks prior to registration)

  • RANDOMIZED PHASE II (ARMS K AND L): Pediatric patients (< 18 years old) must have a creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine based on age/sex as follows:

    • Age: maximum serum creatinine (mg/dL)

      • < 13 years: male (1.2), female (1.2)
      • 13 to < 16 years: male (1.5), female (1.4)
      • >= 16 years: male (1.7), female (1.4)
  • RANDOMIZED PHASE II (ARMS K AND L): No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response

  • RANDOMIZED PHASE II (ARMS K AND L): Patient must have no current or prior history of CNS involvement

  • RANDOMIZED PHASE II (ARMS K AND L): All prior therapy must have been completed at least 21 days prior to enrollment (6 weeks for nitrosoureas or mitomycin C); no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed

  • RANDOMIZED PHASE II (ARMS K AND L): No history of Steven's Johnson's syndrome, TENs syndrome, or motor neuropathy

  • RANDOMIZED PHASE II (ARMS K AND L): HIV positive patients are eligible provided they meet the other protocol criteria including the following:

    • Long term survival expected were it not for the cHL
    • HIV viral loads undetectable by standard clinical HIV testing
    • Willing to adhere to effective combination antiretroviral therapy
  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have autoimmune disorders, prior solid organ transplant, or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of steroid medication for at least 2 weeks prior to initiation of therapy are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study; exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other CNS autoimmune disease (e.g., Multiple sclerosis); patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have grade 2 or greater peripheral sensory neuropathy

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have NYHA class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have a serious medical or psychiatric illness likely to interfere with study participation

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration

  • RANDOMIZED PHASE II (ARMS K AND L): Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not currently be smoking tobacco or other agents; vaping is not allowed

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have a history of or evidence of cardiovascular risks including any of the following:

    • QT interval corrected for heart rate using the Bazett's formula QTcB >= 480 msec at baseline
    • History of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within the past 24 weeks prior to registration
    • History prior to registration or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system
    • Left ventricular ejection fraction (LVEF) =< lower limit of normal on cardiac echocardiogram (echo) or multigated acquisition scan (MUGA)
    • Intra-cardiac defibrillator
    • History of abnormal cardiac valve morphology (>= grade 2) documented by ECHO; (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study); subjects with moderate valvular thickening should not be entered on study
    • History or evidence of current clinically significant uncontrolled cardiac arrhythmias; clarification: subjects with atrial fibrillation controlled for > 30 days prior to dosing are eligible
    • Treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Phase I Arm I (brentuximab vedotin, ipilimumab)

Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

Given IV

Altri nomi:
  • Anticorpo monoclonale antigene-4 anti-citotossico associato ai linfociti T
  • BMS-734016
  • Ipilimumab biosimilare CS1002
  • MDX-010
  • MDX-CTLA4
  • Yevoy
  • MDX010
  • BMS734016
  • BMS 734016

Undergo CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo biopsy

Altri nomi:
  • Bx
  • BIOPSY_TYPE
  • Biopsia

Undergo collection of blood

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Given IV

Altri nomi:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Coniugato anticorpo-farmaco anti-CD30 SGN-35
  • Anticorpo monoclonale anti-CD30-MMAE SGN-35
  • Anticorpo monoclonale anti-CD30-Monomethylaurstatin E SGN-35
  • SGN35
  • SGN 35

Undergo PET

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)
Sperimentale: Phase I Arm II (brentuximab vedotin, nivolumab)

Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

Undergo CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo biopsy

Altri nomi:
  • Bx
  • BIOPSY_TYPE
  • Biopsia

Undergo collection of blood

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Given IV

Altri nomi:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Coniugato anticorpo-farmaco anti-CD30 SGN-35
  • Anticorpo monoclonale anti-CD30-MMAE SGN-35
  • Anticorpo monoclonale anti-CD30-Monomethylaurstatin E SGN-35
  • SGN35
  • SGN 35

Undergo PET

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)

Given IV

Altri nomi:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilare CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab biosimilare ABP 206
  • BCD-263
  • Nivolumab biosimilare BCD-263
  • BMS936558
  • ONO4538
Sperimentale: Phase I Arm III (brentuximab vedotin, nivolumab, ipilimumab)

Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

Given IV

Altri nomi:
  • Anticorpo monoclonale antigene-4 anti-citotossico associato ai linfociti T
  • BMS-734016
  • Ipilimumab biosimilare CS1002
  • MDX-010
  • MDX-CTLA4
  • Yevoy
  • MDX010
  • BMS734016
  • BMS 734016

Undergo CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo biopsy

Altri nomi:
  • Bx
  • BIOPSY_TYPE
  • Biopsia

Undergo collection of blood

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Given IV

Altri nomi:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Coniugato anticorpo-farmaco anti-CD30 SGN-35
  • Anticorpo monoclonale anti-CD30-MMAE SGN-35
  • Anticorpo monoclonale anti-CD30-Monomethylaurstatin E SGN-35
  • SGN35
  • SGN 35

Undergo PET

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)

Given IV

Altri nomi:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilare CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab biosimilare ABP 206
  • BCD-263
  • Nivolumab biosimilare BCD-263
  • BMS936558
  • ONO4538
Sperimentale: Phase II Arm I (brentuximab vedotin, nivolumab)

Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

Undergo CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo biopsy

Altri nomi:
  • Bx
  • BIOPSY_TYPE
  • Biopsia

Undergo collection of blood

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Given IV

Altri nomi:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Coniugato anticorpo-farmaco anti-CD30 SGN-35
  • Anticorpo monoclonale anti-CD30-MMAE SGN-35
  • Anticorpo monoclonale anti-CD30-Monomethylaurstatin E SGN-35
  • SGN35
  • SGN 35

Undergo PET

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)

Given IV

Altri nomi:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilare CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab biosimilare ABP 206
  • BCD-263
  • Nivolumab biosimilare BCD-263
  • BMS936558
  • ONO4538
Sperimentale: Phase II Arm II (brentuximab vedotin, nivolumab, ipilimumab)

Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

Given IV

Altri nomi:
  • Anticorpo monoclonale antigene-4 anti-citotossico associato ai linfociti T
  • BMS-734016
  • Ipilimumab biosimilare CS1002
  • MDX-010
  • MDX-CTLA4
  • Yevoy
  • MDX010
  • BMS734016
  • BMS 734016

Undergo CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo biopsy

Altri nomi:
  • Bx
  • BIOPSY_TYPE
  • Biopsia

Undergo collection of blood

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Given IV

Altri nomi:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Coniugato anticorpo-farmaco anti-CD30 SGN-35
  • Anticorpo monoclonale anti-CD30-MMAE SGN-35
  • Anticorpo monoclonale anti-CD30-Monomethylaurstatin E SGN-35
  • SGN35
  • SGN 35

Undergo PET

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)

Given IV

Altri nomi:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilare CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab biosimilare ABP 206
  • BCD-263
  • Nivolumab biosimilare BCD-263
  • BMS936558
  • ONO4538

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Maximum tolerated dose (MTD) of each combination (Phase I)
Lasso di tempo: 21 days

MTD defined as the highest dose level at which less than 33% of 6 patients experience a dose limiting toxicity, will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Upon completion of the trial, frequency of subjects experiencing toxicities will be tabulated. Toxicities will be assessed and graded according to CTCAE version 4.0 terminology. Exact 95% confidence intervals (CI) around the toxicity proportions will be calculated.

21 days
CR rate (Phase II)
Lasso di tempo: Up to 10 years

The analysis of CR between two arms will be performed using exact Cochran-Mantel-Haenszel (CMH) test stratifying on prior brentuximab vedotin (BV) (yes versus [vs.] no) and age (< 18 vs. >= 18). Multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes.

Up to 10 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Complete response (CR) rate (Phase I)
Lasso di tempo: Up to 3 years

Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI.

Up to 3 years
Partial response (PR) rate (Phase I)
Lasso di tempo: Up to 3 years

Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI.

Up to 3 years
Overall response rate (ORR) rate (Phase I)
Lasso di tempo: Up to 3 years

Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI.

Up to 3 years
Duration of response (DOR) (Phase I)
Lasso di tempo: From the documented beginning of response up to 3 years

DOR will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates. Descriptive statistics will be used to evaluate the DOR achieved with the protocol therapy and with the most recent prior systemic therapy.

From the documented beginning of response up to 3 years
Overall survival (OS) (Phase I)
Lasso di tempo: From the date of study entry up to 3 years

OS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates.

From the date of study entry up to 3 years
Progression-free survival (PFS) (Phase I)
Lasso di tempo: From entry onto study up to 3 years

PFS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates.

From entry onto study up to 3 years
ORR (Phase II)
Lasso di tempo: Up to 10 years

Assessed using Revised Response (Cheson) and Deauville criteria. The analysis of ORR between two arms will be performed using the CMH test stratifying on prior BV (yes vs. no) and age (< 18 vs. >= 18). Multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes.

Up to 10 years
PFS (or modified PFS) (Phase II)
Lasso di tempo: From randomization up to 10 years

PFS will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 95% confidence intervals.

From randomization up to 10 years
OS (Phase II)
Lasso di tempo: From randomization up to 10 years

OS will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 95% confidence intervals.

From randomization up to 10 years
DOR (Phase II)
Lasso di tempo: From the documented beginning of response up to 10 years

DOR, will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 90% confidence intervals. The DOR achieved with the most recent prior systemic therapy will be collected on the case report forms, and descriptive statistics will be used to evaluate the DOR achieved with the protocol therapy and with the most recent prior systemic therapy.

From the documented beginning of response up to 10 years

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Effetti delle associazioni sull'immunità sistemica (Fase I e II)
Lasso di tempo: Basale fino a 6 settimane dopo il completamento del trattamento in studio
Basale fino a 6 settimane dopo il completamento del trattamento in studio
Change in the percentage of activated T cells and natural killer cells (Phase I and II)
Lasso di tempo: Baseline (Time 1) to 9 weeks (Time 3, time of first re-staging)

These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year versus (vs.) those who are event-free at one year will be evaluated.

Baseline (Time 1) to 9 weeks (Time 3, time of first re-staging)
Change in the percentages of activated T cells and natural killer cells (Phase I and II)
Lasso di tempo: Day 1 of cycle 2 (Time 2) or 9 weeks (Time 3) to up to 6 weeks after completion of study treatment (Time 4, end of study)

These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using the Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year vs. those who are event-free at one year will be evaluated.

Day 1 of cycle 2 (Time 2) or 9 weeks (Time 3) to up to 6 weeks after completion of study treatment (Time 4, end of study)
Pre- and post-treatment levels of cytokines and T cell specific biomarkers (Phase I and II)
Lasso di tempo: Baseline to up to 6 weeks after completion of study treatment

Pre- and post-treatment levels of these markers will be compared using the Wilcoxon signed-rank test with two-sided type I error of 0.1. Marker levels between patients who fail at 1-year vs. patients who are event-free at 1-year will be evaluated. Given limited data, the analyses of PD-1, co-expression of Tim-3 with PD-1, ICOS, sCD30, galectin-1 and the peripheral blood absolute lymphocyte to monocyte ratio will be mainly exploratory and will be summarized descriptively at the time-points described above. The association with PFS will be explored.

Baseline to up to 6 weeks after completion of study treatment
Differentially expressed genes between two groups (patients who fail at 1-year vs. patients who are event-free at 1-year or responders vs. non-responders) (Phase I and II)
Lasso di tempo: 1 year

Assessed using gene expression profiling (GEP). Differentially expressed genes will be identified using a rank-based method developed by Dr. Hong (RankProd, R package, Bioconductor Project) with multiple comparison adjustment using a false discovery rate approach. A two-way unsupervised hierarchical clustering analysis will be applied to both the genes and the samples to illustrate whether GEP can separate two groups or is associated with other clinical factors. The genes ranked as most significant will be assessed by gene ontology and pathway analysis for their potential functions in lymphoma biology and treatment failure.

1 year
Microbiome analysis (Phase I and II)
Lasso di tempo: Completion of study treatment

Will compare the gut microbiome between Hodgkin lymphoma (HL) patients and healthy controls with respect to global diversity, taxonomic abundance, and bacterial functional pathways. The relative abundance of each taxon (phyla to genera) and functional pathways among different groups will be statistically compared in univariate analysis using t-test (or Wilcoxon test) and in multivariate analysis using logistic regression. Global diversity tests and multivariate analysis for taxonomic abundance and functional pathways will be adjusted for potential confounders (age, sex, race, and body mass index) in the comparisons of HL patients and controls, and further adjusted for stage and grade when examining the clinical response among HL patients.

Completion of study treatment
Absolute maximum standard uptake value (SUVmax) (Phase II)
Lasso di tempo: Up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, event free survival (EFS), OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (Kaplan-Meier [KM] curve and log-rank testing).

Up to cycle 10
Metabolic whole body tumor volume (MTV) and tumor lesion glycolysis (TLG)
Lasso di tempo: Up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing).

Up to cycle 10
Percent change in SUVmax, MTV and TLG between baseline and during therapy
Lasso di tempo: Baseline up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing).

Baseline up to cycle 10
Percent change in size (sum of perpendicular diameters [SPD]) on computed tomography (CT)
Lasso di tempo: Baseline up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing).

Baseline up to cycle 10
Absolute CT tumor volumes
Lasso di tempo: Up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing).

Up to cycle 10
Percent change in CT size (SPD) and in CT tumor volume between baseline and during therapy
Lasso di tempo: Baseline up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing).

Baseline up to cycle 10

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Catherine S Diefenbach, ECOG-ACRIN Cancer Research Group

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 marzo 2014

Completamento primario (Stimato)

30 giugno 2027

Completamento dello studio (Stimato)

30 giugno 2027

Date di iscrizione allo studio

Primo inviato

8 luglio 2013

Primo inviato che soddisfa i criteri di controllo qualità

8 luglio 2013

Primo Inserito (Stimato)

11 luglio 2013

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi